Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Author
Peterlongo, P.
Chang-Claude, J.
Moysich, K. B.
Rudolph, A.
Schmutzler, R. K.
Simard, J.
Soucy, P.
Eeles, R. A.
Easton, D. F.
Hamann, U.
Wilkening, S.
Chen, B.
Rookus, M. A.
Schmidt, M. K.
van der Baan, F. H.
Spurdle, A. B.
Walker, L. C.
Lose, F.
Maia, A. T.
Montagna, M.
Matricardi, L.
Lubinski, J.
Jakubowska, A.
Gomez Garcia, E. B.
Olopade, O. I.
Nussbaum, R. L.
Nathanson, K. L.
Domchek, S. M.
Rebbeck, T. R.
Arun, B. K.
Karlan, B. Y.
Orsulic, S.
Lester, J.
Chung, W. K.
Miron, A.
Southey, M. C.
Goldgar, D. E.
Buys, S. S.
Janavicius, R.
Dorfling, C. M.
van Rensburg, E. J.
Ding, Y. C.
Neuhausen, S. L.
Hansen, T. V.
Gerdes, A. M.
Ejlertsen, B.
Jonson, L.
Osorio, A.
Martinez-Bouzas, C.
Benitez, J.
Conway, E. E.
Blazer, K. R.
Weitzel, J. N.
Manoukian, S.
Peissel, B.
Zaffaroni, D.
Scuvera, G.
Barile, M.
Ficarazzi, F.
Mariette, F.
Fortuzzi, S.
Viel, A.
Giannini, G.
Papi, L.
Martayan, A.
Tibiletti, M. G.
Radice, P.
Vratimos, A.
Fostira, F.
Garber, J. E.
Donaldson, A.
Brewer, Carole
Foo, C.
Evans, D. G.
Frost, D.
Eccles, D.
Brady, A.
Cook, J.
Tischkowitz, M.
Adlard, J.
Barwell, J.
Walker, L.
Izatt, L.
Side, L. E.
Kennedy, M. J.
Rogers, M. T.
Porteous, M. E.
Morrison, P. J.
Platte, R.
Davidson, R.
Hodgson, S. V.
Ellis, S.
Cole, T.
Embrace,
Godwin, A. K.
Claes, K.
Van Maerken, T.
Meindl, A.
Gehrig, A.
Sutter, C.
Engel, C.
Niederacher, D.
Steinemann, D.
Plendl, H.
Kast, K.
Rhiem, K.
Ditsch, N.
Arnold, N.
Varon-Mateeva, R.
Wappenschmidt, B.
Wang-Gohrke, S.
Bressac-de Paillerets, B.
Buecher, B.
Delnatte, C.
Houdayer, C.
Stoppa-Lyonnet, D.
Damiola, F.
Coupier, I.
Barjhoux, L.
Venat-Bouvet, L.
Golmard, L.
Boutry-Kryza, N.
Sinilnikova, O. M.
Caron, O.
Pujol, P.
Mazoyer, S.
Belotti, M.
Gemo Study Collaborators
Piedmonte, M.
Friedlander, M. L.
Rodriguez, G. C.
Copeland, L. J.
de la Hoya, M.
Segura, P. P.
Nevanlinna, H.
Aittomaki, K.
van Os, T. A.
Meijers-Heijboer, H. E.
van der Hout, A. H.
Vreeswijk, M. P.
Hoogerbrugge, N.
Ausems, M. G.
van Doorn, H. C.
Collee, J. M.
Hebon,
Olah, E.
Diez, O.
Blanco, I.
Lazaro, C.
Brunet, J.
Feliubadalo, L.
Cybulski, C.
Gronwald, J.
Durda, K.
Jaworska-Bieniek, K.
Sukiennicki, G.
Arason, A.
Chiquette, J.
Teixeira, M. R.
Olswold, C.
Couch, F. J.
Lindor, N. M.
Wang, X.
Szabo, C. I.
Offit, K.
Corines, M.
Jacobs, L.
Robson, M. E.
Zhang, L.
Joseph, V.
Berger, A.
Singer, C. F.
Rappaport, C.
Kaulich, D. G.
Pfeiler, G.
Tea, M. K.
Phelan, C. M.
Greene, M. H.
Mai, P. L.
Rennert, G.
Mulligan, A. M.
Glendon, G.
Tchatchou, S.
Andrulis, I. L.
Toland, A. E.
Bojesen, A.
Pedersen, I. S.
Thomassen, M.
Jensen, U. B.
Laitman, Y.
Rantala, J.
von Wachenfeldt, A.
Ehrencrona, H.
Askmalm, M. S.
Borg, A.
Kuchenbaecker, K. B.
McGuffog, L.
Barrowdale, D.
Healey, S.
Lee, A.
Pharoah, P. D.
Chenevix-Trench, G.
K. ConFab Investigators
Antoniou, A. C.
Friedman, E.
Date
2015-01-01Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyType
Journal ArticleResearch Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Publisher
Cancer Epidemiol Biomarkers PrevDOI
10.1158/1055-9965.EPI-14-0532Metadata
Show full item recordAbstract
BACKGROUND: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. METHODS: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. RESULTS: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. CONCLUSION: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. IMPACT: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies.